Versant Ventures — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Lycia Therapeutics develops LYTAC degrader therapeutics designed to selectively reduce levels of disease-causing extracellular and membrane-bound proteins.
BiotechHealthtechSouth San Francisco, US
Tim Anderson(Director)William Rieflin(Director)Aetna Wun Trombley(Executive Officer, Director)Laurent Fischer(Director)Ming Fang(Director)Amy Bachrodt(Executive Officer)
Board seatClare Ozawa· per SEC Form D · $75M raise · filed Jun 2026
BiotechLittleton, US
Andrew Phillips(Executive Officer, Director)
BoardAli Behbahani(Director)
Board seatCarlo Rizzuto· per SEC Form D · $60M raise · filed Mar 2026
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.